BioVantra
Client Portal Request Information →
Resources / IPCT Overview

Integrated Prostate
Cytomolecular Testing Overview.

BioVantra’s Integrated Prostate Cytomolecular Testing (IPCT) brings prostate FNA cytology, TMPRSS2-ERG FISH, whole-gland sector mapping, and a Genetic Complexity Score (GCS) together into a single structured report. The goal is not to add more data, but to organize morphologic, molecular, and spatial information into a more coherent whole-gland interpretation for prostate cancer diagnosis and treatment planning.

Request Information → View IPCT service
Topic
Clinical overview
Service
IPCT
Audience
Urologists & clinical teams
01 · Why this integrated approach

Four components,
read as one case.

The intent behind IPCT is not to add more data to an already crowded clinical picture. It is to organize morphologic, molecular, and spatial information into a single, more coherent interpretation of the gland.

A

Morphology from prostate FNA cytology

Fine-needle aspiration contributes cellular, morphologic assessment of sampled tissue and forms the morphologic foundation of the integrated interpretation.

B

Molecular context from TMPRSS2-ERG FISH

FISH for the TMPRSS2-ERG rearrangement adds complementary molecular information that is reviewed together with cytology rather than in isolation.

C

Spatial context from sector mapping

Multi-sector sampling provides a spatial view of the gland, supporting a broader read of the case than one limited to a single sampled tumor focus.

D

Biologic context from GCS

The Genetic Complexity Score (GCS) adds biologic context that supports interpretation of the overall case in addition to sector-level findings.

02 · Role of prostate FNA

Morphologic assessment,
sector by sector.

Fine-needle aspiration gives a cellular, morphologic view of the tissue sampled. In IPCT, FNA specimens are obtained from multiple prostate sectors so that cytologic findings can be reviewed at the level of individual sectors and across the gland as a whole.

  • A

    Cellular morphologic assessment

    Cytologic review describes the cellular features of each specimen and supports specimen-level characterization of benign, atypical, and malignant findings.

  • B

    Multi-sector sampling

    Specimens are obtained from defined sectors of the prostate, which allows morphologic findings to be mapped to specific regions of the gland rather than reviewed as a single pooled result.

  • C

    Sector-level and whole-gland interpretation

    Reviewing sectors together supports both a local read of individual regions and a broader read of how findings distribute across the gland.

  • D

    Perspective beyond a single focus

    Because multiple sectors are characterized, the case can be interpreted with more context than a view limited to a single sampled tumor focus.

03 · Role of TMPRSS2-ERG FISH

Complementary
molecular context.

Fluorescence in situ hybridization (FISH) is used to detect prostate cancer-associated TMPRSS2-ERG gene rearrangements. When present, these rearrangements are highly specific for prostatic malignancy and define a molecular subtype with distinct biologic features. FISH results are interpreted alongside cytology, not in isolation, and absence of a rearrangement does not exclude malignancy.

A

Detects prostate cancer-associated rearrangements

FISH assays for TMPRSS2-ERG gene rearrangements, a class of structural abnormalities that arise in prostatic epithelium and are closely associated with prostate cancer.

B

Highly specific when present

When a TMPRSS2-ERG rearrangement is identified, the finding is highly specific for prostatic malignancy and defines a molecular subtype with distinct biologic features.

C

Interpreted together with cytology

FISH results are reviewed on the same case as the cytologic findings, so morphologic and molecular information inform one another rather than being read on separate reports.

D

Absence does not exclude malignancy

Not every prostate cancer carries a TMPRSS2-ERG rearrangement. A negative FISH result is informative but does not, on its own, rule out malignancy.

04 · Whole-gland mapping and GCS

Spatial and biologic
context, together.

Sector mapping and the Genetic Complexity Score (GCS) address two different questions about the same case: where findings sit across the gland, and how molecularly complex those findings appear. Together they support a broader, more structured read of the prostate.

  • A

    Why sector mapping matters

    Mapping findings across defined prostate sectors supports a spatial, whole-gland view rather than a view centered on a single dominant lesion.

  • B

    Concordant, discordant, indeterminate, negative

    Sectors may be characterized as concordant, discordant, indeterminate, or negative. This shared vocabulary supports clearer reading of the case and consistent discussion across teams.

  • C

    GCS is a composite molecular measure

    The Genetic Complexity Score is a composite measure derived from the type and distribution of TMPRSS2-ERG abnormalities observed on FISH. It incorporates factors such as rearrangement type, number of abnormal cells, heterogeneity across the specimen, and associated copy number alteration.

  • D

    Stratified low, moderate, or high

    GCS is reported as low, moderate, or high. Higher scores reflect greater molecular complexity and may indicate increased biologic heterogeneity within the sampled tissue.

  • E

    Beyond the dominant lesion

    Integrated, sector-based reporting with GCS adds biologic context to the integrated interpretation and may help characterize disease beyond the dominant lesion, including focality and laterality across the gland.

05 · Relationship to MRI, core biopsy, and other testing

Additive and integrative,
not a replacement.

IPCT is intended to work alongside existing diagnostic pathways. It does not replace MRI, core needle biopsy, or histopathology. Its contribution is the way morphologic, molecular, and spatial information are organized together so that the resulting report is easier to read in context with the rest of the clinical picture.

A

Complements MRI

Sector-level results can be read alongside MRI, supporting correlation of imaging-visible lesions with cytologic and molecular findings from the same region.

B

Complements core needle biopsy and histopathology

IPCT is additive to, not a substitute for, core needle biopsy and standard histopathology. It contributes an integrated, sector-based perspective to the shared clinical record.

C

Supports interpretation and planning conversations

The integrated report may assist interpretation, risk stratification, multidisciplinary communication, biopsy planning, and treatment planning by presenting relevant information in a single structured format.

D

Additive, not a replacement

IPCT should be understood as a complement to the existing prostate cancer diagnostic pathway, not as a substitute for any of its established components.

06 · Practical clinical value

What a referring urologist
can expect to use.

In day-to-day use, the integrated report surfaces a short list of practical takeaways that referring urologists can read alongside the rest of the clinical picture.

  • A

    Correlation with MRI-visible lesions

    Sector-level findings can be read against MRI to support correlation between imaging-visible lesions and cytologic / molecular results.

  • B

    Specimen-level cytologic grading

    Each specimen is characterized morphologically, supporting specimen-level reading rather than a single pooled summary for the case.

  • C

    Integrated molecular confirmation

    Molecular information is presented together with cytology so that complementary findings are visible in one place during review.

  • D

    Whole-gland diagnostic mapping

    Sector-based reporting describes how findings distribute across the gland, supporting a whole-gland view of the case.

  • E

    Broader context for disease distribution

    The integrated format may help characterize focality and laterality and identify findings beyond the dominant lesion.

  • F

    Clearer structured reporting

    Consistent terminology and synoptic formatting make the case easier to read, reference, and discuss across multidisciplinary teams.

Downloadable PDFs

Download physician-facing PDF materials related to Integrated Prostate Cytomolecular Testing and report interpretation.

PDF 01

Integrated Prostate Cytomolecular Testing Overview

A concise physician-facing overview of the service, report structure, and clinical value.

Open PDF →
PDF 02

Curated Clinical Case & Sample Report

A physician-facing case companion followed by a sample Integrated Prostate Cytomolecular Report.

Open PDF →
07 · Selected references

Selected references.

A short, non-exhaustive list of peer-reviewed literature on TMPRSS2-ERG rearrangements in prostate cancer, provided for clinical reference.

  1. Demichelis, F., Fall, K., Perner, S., et al. (2007). TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene, 26(31), 4596–4599.
  2. Perner, S., Demichelis, F., Beroukhim, R., et al. (2006). TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Research, 66(17), 8337–8341.
  3. Yoshimoto, M., Ludkovski, O., Bayani, J., et al. (2006). TMPRSS2:ERG gene fusions resulting from a novel mechanism involving complex genomic rearrangements. Cancer Research, 66(22), 10622–10629.
  4. Weier, C., Haffner, M.C., Mosbruger, T., et al. (2013). Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. The Journal of Pathology, 230(2), 174–183.
  5. Attard, G., Clark, J., Ambroisine, L., et al. (2008). Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene, 27(3), 253–263.
Connect with BioVantra

Talk to us about integrated prostate diagnostics.

We work with urology practices and clinical teams involved in prostate cancer diagnosis and treatment. Share a little about your setting and a member of our team will follow up to discuss how IPCT may fit into your workflow.

Request Information → Contact our team
Existing client? Access diagnostic reports and case history through the Client Portal
Emailcontact@biovantra.com
Phone(352) 861-2296
Fax(352) 671-2737
Address9401 SW Highway 200
STE 502
Ocala, FL 34481-9650